Research by scientists at the University of Sheffield suggests that the combination of zoledronic acid (a drug used to prevent bone loss) and chemotherapy agent doxorubicin could stop the growth of breast cancer tumours. Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "Breakthrough welcomes any research which investigates new uses for existing treatments to help benefit people with breast cancer.
More...